Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Blattella germanica allergenic extract is a biological product derived from the German cockroach, used for both diagnosing and treating cockroach allergies. As a diagnostic, it is used in skin prick tests and nasal allergen challenges (NAC) to confirm sensitization. As a therapeutic, it is being investigated as an allergen-specific immunotherapy, primarily through subcutaneous injections (SCIT), to treat allergic conditions like asthma and perennial allergic rhinitis, particularly in urban children. The extract contains multiple allergens, including the major allergens Bla g 1 and Bla g 2, which trigger IgE-mediated responses in sensitized individuals. The goal of immunotherapy with this extract is to induce immune tolerance by modulating the body's response, which involves shifting from a Th2-driven allergic reaction to a more tolerant state, characterized by the production of blocking IgG antibodies and a reduction in inflammatory cytokines. The National Institute of Allergy and Infectious Diseases (NIAID) and the Inner City Asthma Consortium (ICAC) have sponsored several clinical trials to evaluate its efficacy and safety.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on blattella germanica allergenic extract.